Search

Your search keyword '"Garza C"' showing total 1,175 results
Start Over Author "Garza C"
1,175 results on '"Garza C"'

3. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Author

Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., Lambertini M., Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., and Lambertini M.

Abstract

Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)-low-expressing BC has recently emerged as a novel therapeutic target but has not been characterized in this rare patient subset. Methods: Women aged ≤40 years with newly diagnosed early-stage HER2-negative BC (HER2-0 and HER2-low) and germline BRCA1/2 PVs from 78 health care centers worldwide were retrospectively included. Chi-square test and Student t-test were used to describe variable distribution between HER2-0 and HER2-low. Associations with HER2-low status were assessed with logistic regression. Kaplan–Meier method and Cox regression analysis were used to assess disease-free survival (DFS) and overall survival. Statistical significance was considered for p ≤.05. Results: Of 3547 included patients, 32.3% had HER2-low BC, representing 46.3% of hormone receptor–positive and 21.3% of triple-negative (TN) tumors. HER2-low vs. HER2-0 BC were more often of grade 1/2 (p <.001), hormone receptor–positive (p <.001), and node-positive (p =.003). BRCA2 PVs were more often associated with HER2-low than BRCA1 PVs (p <.001). HER2-low versus HER2-0 showed better DFS (hazard ratio [HR], 0.86; 95% CI, 0.76–0.97) in the overall population and more favorable DFS (HR, 0.78; 95% CI, 0.64–0.95) and overall survival (HR, 0.65; 95% CI, 0.46–0.93) in the TN subgroup. Luminal A–like tumors in HER2-low (p =.014) and TN and luminal A-like in HER2-0 (p =.019) showed the worst DFS. Conclusions: In young patients with HER2-negative BC and germline BRCA1/2 PVs, HER2-low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal-like disease. HER2-low status was associated with a modestly improved prognosis.

Published
2024

4. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., Partridge A. H., Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., and Partridge A. H.

Abstract

(Abstracted from JAMA 2024;331(1):49-59 Individuals who are diagnosed with breast cancer at a young age are often carriers of a pathogenic variant in the BRCA1 or BRCA2 genes, and many young women in this situation are interested in preserving future fertility, if possible. Reproductive counseling in this situation can be complex due to the risk of passing on the variant, as well as the implications on their own fertility, as the mutation can impact ovarian reserve, fertility potential, and other factors.

Published
2024

6. The satisfactory growth and development at 2 years of age of the INTERGROWTH-21st Fetal Growth Standards cohort support its appropriateness for constructing international standards

Author

Villar, José, Ismail, Leila Cheikh, Urias, Eleonora Staines, Giuliani, Francesca, Ohuma, Eric O, Victora, Cesar G, Papageorghiou, Aris T, Altman, Douglas G, Garza, Cutberto, Barros, Fernando C, Puglia, Fabien, Ochieng, Roseline, Jaffer, Yasmin A, Noble, Julia A, Bertino, Enrico, Purwar, Manorama, Pang, Ruyan, Lambert, Ann, Chumlea, Cameron, Stein, Alan, Fernandes, Michelle, Bhutta, Zulfiqar A, Kennedy, Stephen H, Katz, M, Bhan, MK, Garza, C, Zaidi, S, Langer, A, Rothwell, PM, Weatherall, D, Bhutta, ZA, Villar, J, Kennedy, S, Altman, DG, Barros, FC, Bertino, E, Burton, F, Carvalho, M, Ismail, L Cheikh, Chumlea, WC, Gravett, MG, Jaffer, YA, Lambert, A, Lumbiganon, P, Noble, JA, Pang, RY, Papageorghiou, AT, Purwar, M, Rivera, J, Victora, C, Shorten, M, Hoch, L, Knight, HE, Ohuma, EO, Cosgrove, C, Blakey, I, Urias, E Staines, Roseman, F, Kunnawar, N, Gu, SH, Wang, JH, Wu, MH, Domingues, M, Gilli, P, Juodvirsiene, L, Musee, N, Al-Jabri, H, Waller, S, Muninzwa, D, Yellappan, D, Carter, A, Reade, D, Miller, R, Salomon, L, Leston, A, Mitidieri, A, Al-Aamri, F, Paulsene, W, Sande, J, Al-Zadjali, WKS, Batiuk, C, Bornemeier, S, Dighe, M, Gaglioti, P, Jacinta, N, Jaiswal, S, Oas, K, Oberto, M, Olearo, E, Owende, MG, Shah, J, Sohoni, S, Todros, T, Venkataraman, M, Vinayak, S, Wang, L, Wilson, D, Wu, QQ, Zhang, Y, and Chamberlain, P

Subjects
Pediatric, Conditions Affecting the Embryonic and Fetal Periods, Infant Mortality, Clinical Research, Preterm, Low Birth Weight and Health of the Newborn, Nutrition, Prevention, Perinatal Period - Conditions Originating in Perinatal Period, 2.4 Surveillance and distribution, Aetiology, Reproductive health and childbirth, Good Health and Well Being, Brazil, Cephalometry, Child Development, China, Female, Fetal Development, Growth Charts, Health Status, Humans, India, Infant, Infant, Newborn, Italy, Kenya, Longitudinal Studies, Male, Motor Skills, Nutritional Status, Oman, Pregnancy, United Kingdom, United States, World Health Organization, International Fetal and Newborn Growth Consortium for the 21(st) Century (INTERGROWTH-21(st)), INTERGROWTH-21(st) fetal growth standards, development, postnatal growth, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Abstract

BackgroundThe World Health Organization recommends that human growth should be monitored with the use of international standards. However, in obstetric practice, we continue to monitor fetal growth using numerous local charts or equations that are based on different populations for each body structure. Consistent with World Health Organization recommendations, the INTERGROWTH-21st Project has produced the first set of international standards to date pregnancies; to monitor fetal growth, estimated fetal weight, Doppler measures, and brain structures; to measure uterine growth, maternal nutrition, newborn infant size, and body composition; and to assess the postnatal growth of preterm babies. All these standards are based on the same healthy pregnancy cohort. Recognizing the importance of demonstrating that, postnatally, this cohort still adhered to the World Health Organization prescriptive approach, we followed their growth and development to the key milestone of 2 years of age.ObjectiveThe purpose of this study was to determine whether the babies in the INTERGROWTH-21st Project maintained optimal growth and development in childhood.Study designIn the Infant Follow-up Study of the INTERGROWTH-21st Project, we evaluated postnatal growth, nutrition, morbidity, and motor development up to 2 years of age in the children who contributed data to the construction of the international fetal growth, newborn infant size and body composition at birth, and preterm postnatal growth standards. Clinical care, feeding practices, anthropometric measures, and assessment of morbidity were standardized across study sites and documented at 1 and 2 years of age. Weight, length, and head circumference age- and sex-specific z-scores and percentiles and motor development milestones were estimated with the use of the World Health Organization Child Growth Standards and World Health Organization milestone distributions, respectively. For the preterm infants, corrected age was used. Variance components analysis was used to estimate the percentage variability among individuals within a study site compared with that among study sites.ResultsThere were 3711 eligible singleton live births; 3042 children (82%) were evaluated at 2 years of age. There were no substantive differences between the included group and the lost-to-follow up group. Infant mortality rate was 3 per 1000; neonatal mortality rate was 1.6 per 1000. At the 2-year visit, the children included in the INTERGROWTH-21st Fetal Growth Standards were at the 49th percentile for length, 50th percentile for head circumference, and 58th percentile for weight of the World Health Organization Child Growth Standards. Similar results were seen for the preterm subgroup that was included in the INTERGROWTH-21st Preterm Postnatal Growth Standards. The cohort overlapped between the 3rd and 97th percentiles of the World Health Organization motor development milestones. We estimated that the variance among study sites explains only 5.5% of the total variability in the length of the children between birth and 2 years of age, although the variance among individuals within a study site explains 42.9% (ie, 8 times the amount explained by the variation among sites). An increase of 8.9 cm in adult height over mean parental height is estimated to occur in the cohort from low-middle income countries, provided that children continue to have adequate health, environmental, and nutritional conditions.ConclusionThe cohort enrolled in the INTERGROWTH-21st standards remained healthy with adequate growth and motor development up to 2 years of age, which supports its appropriateness for the construction of international fetal and preterm postnatal growth standards.

Published
2018

7. Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better

Author

Martinez-Cannon BA, Barragan-Carrillo R, and Villarreal-Garza C

Subjects
breast cancer, young women, unmet needs, disparities, resource-limited settings, low- and middle-income countries, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Bertha Alejandra Martinez-Cannon,1,2,&ast; Regina Barragan-Carrillo,1,2,&ast; Cynthia Villarreal-Garza2,3 1Hematology-Oncology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; 2Joven & Fuerte: Programa para la Atencion e Investigacion de Mujeres Jovenes con Cancer de Mama en Mexico, Mexico City, Mexico; 3Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico&ast;These authors contributed equally to this workCorrespondence: Bertha Alejandra Martinez-CannonHematology-Oncology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Belisario Dominguez Secc 16, Tlalpan, Mexico City, 14080, MexicoTel +52 55 5487 0900Email amtzcannon@gmail.comAbstract: Young women with breast cancer (YWBC) account for a variable proportion of patients diagnosed with breast cancer around the globe, with a higher prevalence in resource-limited settings than in high-income countries. This group represents a unique population that warrants special attention due to specific biological considerations and age-specific supportive care issues. This review aims to explore existing knowledge regarding YWBC’s needs, particularly in resource-restricted settings. To date, scarce information regarding the care of YWBC in resource-constrained countries is available, with most reports describing suboptimal care in terms of survivorship needs. Health care providers should implement actions to improve endocrine treatment adherence, referrals for fertility counseling and preservation, contraceptive use compliance, timely body image and sexual function interventions, comprehensive genetic risk assessments, and early quality of life and psychosocial health interventions. While high costs act as a barrier for optimal care in resource-limited settings, improving patient education represents a promising and cost-effective solution to improve patient care. Future research on developing tailored educational resources for YWBC in resource-limited settings should be considered a priority.Keywords: breast cancer, young women, unmet needs, disparities, resource-limited settings, low- and middle-income countries

Published
2021

8. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Author

Condorelli, M., Bruzzone, M., Ceppi, M., Ferrari, A., Grinshpun, A., Hamy, A.S., de Azambuja, E., Carrasco, E., Peccatori, F.A., Di Meglio, A., Paluch-Shimon, S., Poorvu, P.D., Venturelli, M., Rousset-Jablonski, C., Senechal, C., Livraghi, L., Ponzone, R., De Marchis, L., Pogoda, K., Sonnenblick, A., Villarreal-Garza, C., Córdoba, O., Teixeira, L., Clatot, F., Punie, K., Graffeo, R., Dieci, M.V., Pérez-Fidalgo, J.A., Duhoux, F.P., Puglisi, F., Ferreira, A.R., Blondeaux, E., Peretz-Yablonski, T., Caron, O., Saule, C., Ameye, L., Balmaña, J., Partridge, A.H., Azim, H.A., Demeestere, I., and Lambertini, M.

Published
2021
Full Text
View/download PDF

9. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

10. International estimated fetal weight standards of the INTERGROWTH‐21st Project

Author

Stirnemann, J, Villar, J, Salomon, LJ, Ohuma, E, Ruyan, P, Altman, DG, Nosten, F, Craik, R, Munim, S, Cheikh Ismail, L, Barros, FC, Lambert, A, Norris, S, Carvalho, M, Jaffer, YA, Noble, JA, Bertino, E, Gravett, MG, Purwar, M, Victora, CG, Uauy, R, Bhutta, Z, Kennedy, S, Papageorghiou, AT, Katz, M, Bhan, MK, Garza, C, Zaidi, S, Langer, A, Rothwell, PM, Weatherall, Sir D, Bhutta, ZA, Burton, F, Ismail, L Cheikh, Chumlea, WC, Lumbiganon, P, Pang, RY, Rivera, J, Victora, C, Berkley, J, Shorten, M, Hoch, L, Knight, HE, Ohuma, EO, Cosgrove, C, Blakey, I, Ash, S, Urias, E Staines, Roseman, F, Kunnawar, N, Gu, SH, Wang, JH, and Wu, MH

Subjects
Conditions Affecting the Embryonic and Fetal Periods, Prevention, Perinatal Period - Conditions Originating in Perinatal Period, Clinical Research, Preterm, Low Birth Weight and Health of the Newborn, Pediatric, Infant Mortality, Reproductive health and childbirth, Adult, Birth Weight, Cross-Sectional Studies, Female, Femur, Fetal Weight, Gestational Age, Head, Humans, Pregnancy, Prospective Studies, Ultrasonography, Prenatal, International Fetal and Newborn Growth Consortium for the 21st Century, Scientific Advisory Committee, Steering Committees, INTERGROWTH-21st, INTERBIO-21st, Executive Committee, In addition for INTERBIO 21st, Project Coordinating Unit, Data Analysis Group, Data Management Group, Ultrasound Group, In addition for INTERBIO-21st:, Anthropometry Group, Laboratory Processing Group, Neonatal Group, Environmental Health Group, Neurodevelopment Group, Participating countries and local investigators, birth weight, fetal growth, gestational age, screening, ultrasound, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Abstract

ObjectiveEstimated fetal weight (EFW) and fetal biometry are complementary measures used to screen for fetal growth disturbances. Our aim was to provide international EFW standards to complement the INTERGROWTH-21st Fetal Growth Standards that are available for use worldwide.MethodsWomen with an accurate gestational-age assessment, who were enrolled in the prospective, international, multicenter, population-based Fetal Growth Longitudinal Study (FGLS) and INTERBIO-21st Fetal Study (FS), two components of the INTERGROWTH-21st Project, had ultrasound scans every 5 weeks from 9-14 weeks' until 40 weeks' gestation. At each visit, measurements of fetal head circumference (HC), biparietal diameter, occipitofrontal diameter, abdominal circumference (AC) and femur length (FL) were obtained blindly by dedicated research sonographers using standardized methods and identical ultrasound machines. Birth weight was measured within 12 h of delivery by dedicated research anthropometrists using standardized methods and identical electronic scales. Live babies without any congenital abnormality, who were born within 14 days of the last ultrasound scan, were selected for inclusion. As most births occurred at around 40 weeks' gestation, we constructed a bootstrap model selection and estimation procedure based on resampling of the complete dataset under an approximately uniform distribution of birth weight, thus enriching the sample size at extremes of fetal sizes, to achieve consistent estimates across the full range of fetal weight. We constructed reference centiles using second-degree fractional polynomial models.ResultsOf the overall population, 2404 babies were born within 14 days of the last ultrasound scan. Mean time between the last scan and birth was 7.7 (range, 0-14) days and was uniformly distributed. Birth weight was best estimated as a function of AC and HC (without FL) as log(EFW) = 5.084820 - 54.06633 × (AC/100)3  - 95.80076 × (AC/100)3  × log(AC/100) + 3.136370 × (HC/100), where EFW is in g and AC and HC are in cm. All other measures, gestational age, symphysis-fundus height, amniotic fluid indices and interactions between biometric measures and gestational age, were not retained in the selection process because they did not improve the prediction of EFW. Applying the formula to FGLS biometric data (n = 4231) enabled gestational age-specific EFW tables to be constructed. At term, the EFW centiles matched those of the INTERGROWTH-21st Newborn Size Standards but, at

Published
2017

11. Pregnancy After Breast Cancer in Young BRCA Carriers

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, Partridge, AH, Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, and Partridge, AH

Abstract

IMPORTANCE: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. OBJECTIVE: To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. EXPOSURE: Pregnancy after breast cancer. MAIN OUTCOMES AND MEASURES: Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. RESULTS: Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patie

Published
2024

12. Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer

Author

Martinez-Cannon BA, Castro-Sanchez A, Barragan-Carrillo R, de la Rosa Pacheco S, Platas A, Fonseca A, Vega Y, Bojorquez-Velazquez K, Bargallo-Rocha JE, Mohar A, and Villarreal-Garza C

Subjects
young women, breast cancer, tamoxifen, adherence, mexico, Medicine (General), R5-920
Abstract

Bertha Alejandra Martinez-Cannon,1,2 Andrea Castro-Sanchez,2 Regina Barragan-Carrillo,2 Sylvia de la Rosa Pacheco,1 Alejandra Platas,2,3 Alan Fonseca,2,3 Yoatzin Vega,2 Karen Bojorquez-Velazquez,3 Juan Enrique Bargallo-Rocha,2,3 Alejandro Mohar,3,4 Cynthia Villarreal-Garza1,2 1Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; 2Joven & Fuerte: Programa para la Atencion e Investigacion de Mujeres Jovenes con Cancer de Mama, Mexico City, Mexico; 3Departamento de Investigacion y de Tumores Mamarios, Instituto Nacional de Cancerologia, Mexico City, Mexico; 4Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, Mexico City, MexicoCorrespondence: Cynthia Villarreal-GarzaBreast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, Av. Batallon de San Patricio 112, Real San Agustin, 66278, San Pedro Garza Garcia, Nuevo Leon, MexicoEmail cynthiavg@gmail.comBackground: Breast cancer (BC) in young women is characterized by an unfavorable prognosis in hormone receptor-positive/HER2-negative tumors, which may be explained by low rates of tamoxifen adherence. In Mexico, up to 14% of all BC diagnoses occur in young women and no data on tamoxifen adherence has been reported.Objective: To estimate the rate of adherence to adjuvant tamoxifen in Mexican young women with BC (YWBC).Methods: A cross-sectional survey was conducted at the National Cancer Institute in Mexico City, among YWBC (≤ 40 years at diagnosis) receiving adjuvant tamoxifen. Adherence was measured subjectively, through self-reported surveys, and objectively, through medication possession ratio (MPR). Descriptive statistics were used to analyze sociodemographic characteristics. To compare associations between patients’ characteristics and adherence, Chi-square test was used for categorical variables and Student’s t-test or Mann–Whitney U-test for quantitative variables.Results: A total of 141 YWBC receiving adjuvant tamoxifen were included. Regarding subjective adherence, 95% expressed taking tamoxifen regularly, 70% reported missing 0 doses in the past 30 days, and 71.6% reported having adverse effects. Regarding objective adherence, 74.8% of patients had an MPR ≥ 80%. The association between subjective and objective adherence was statistically significant (p = 0.004). Subjective adherence was associated with not skipping tamoxifen doses when feeling worse. Objective adherence was associated with having a stable job, not skipping tamoxifen doses when feeling worse, taking additional medications, and time on tamoxifen treatment. Fifty-six percent considered the information on tamoxifen to be insufficient and 37% not understandable.Conclusion: In our study, high subjective and objective adherence rates to adjuvant tamoxifen were reported, although an important proportion of women reported high rates of adverse effects and not fully understanding the benefits of tamoxifen. Strategies to increase tamoxifen adherence may be even more important now that longer durations of treatment or further ovarian function suppression have become the standard of care in YWBC.Keywords: young women, breast cancer, tamoxifen, adherence, Mexico

Published
2021

13. Achieving accurate estimates of fetal gestational age and personalised predictions of fetal growth based on data from an international prospective cohort study: a population-based machine learning study

Author

Norris, S, Abbott, SE, Abubakar, A, Acedo, J, Ahmed, I, Al-Aamri, F, Al-Abduwani, J, Al-Abri, J, Alam, D, Albernaz, E, Algren, H, Al-Habsi, F, Alija, M, Al-Jabri, H, Al-Lawatiya, H, Al-Rashidiya, B, Altman, DG, Al-Zadjali, WK, Andersen, HF, Aranzeta, L, Ash, S, Baricco, M, Barros, FC, Barsosio, H, Batiuk, C, Batra, M, Berkley, J, Bertino, E, Bhan, MK, Bhat, BA, Bhutta, ZA, Blakey, I, Bornemeier, S, Bradman, A, Buckle, M, Burnham, O, Burton, F, Capp, A, Cararra, VI, Carew, R, Carrara, VI, Carter, AA, Carvalho, M, Chamberlain, P, Cheikh, Ismail L, Cheikh Ismail, L, Choudhary, A, Choudhary, S, Chumlea, WC, Condon, C, Corra, LA, Cosgrove, C, Craik, R, da Silveira, MF, Danelon, D, de Wet, T, de Leon, E, Deshmukh, S, Deutsch, G, Dhami, J, Di, Nicola P, Dighe, M, Dolk, H, Domingues, M, Dongaonkar, D, Enquobahrie, D, Eskenazi, B, Farhi, F, Fernandes, M, Finkton, D, Fonseca, S, Frederick, IO, Frigerio, M, Gaglioti, P, Garza, C, Gilli, G, Gilli, P, Giolito, M, Giuliani, F, Golding, J, Gravett, MG, Gu, SH, Guman, Y, He, YP, Hoch, L, Hussein, S, Ibanez, D, Ioannou, C, Jacinta, N, Jackson, N, Jaffer, YA, Jaiswal, S, Jimenez-Bustos, JM, Juangco, FR, Juodvirsiene, L, Katz, M, Kemp, B, Kennedy, S, Ketkar, M, Khedikar, V, Kihara, M, Kilonzo, J, Kisiang'ani, C, Kizidio, J, Knight, CL, Knight, HE, Kunnawar, N, Laister, A, Lambert, A, Langer, A, Lephoto, T, Leston, A, Lewis, T, Liu, H, Lloyd, S, Lumbiganon, P, Macauley, S, Maggiora, E, Mahorkar, C, Mainwaring, M, Malgas, L, Matijasevich, A, McCormick, K, McGready, R, Miller, R, Min, A, Mitidieri, A, Mkrtychyan, V, Monyepote, B, Mota, D, Mulik, I, Munim, S, Muninzwa, D, Musee, N, Mwakio, S, Mwangudzah, H, Napolitano, R, Newton, CR, Ngami, V, Noble, JA, Norris, T, Nosten, F, Oas, K, Oberto, M, Occhi, L, Ochieng, R, Ohuma, EO, Olearo, E, Olivera, I, Owende, MG, Pace, C, Pan, Y, Pang, RY, Papageorghiou, AT, Patel, B, Paul, V, Paulsene, W, Puglia, F, Purwar, M, Rajan, V, Raza, A, Reade, D, Rivera, J, Rocco, DA, Roseman, F, Roseman, S, Rossi, C, Rothwell, PM, Rovelli, I, Saboo, K, Salam, R, Salim, M, Salomon, L, Sanchez, Luna M, Sande, J, Sarris, I, Savini, S, Sclowitz, IK, Seale, A, Shah, J, Sharps, M, Shembekar, C, Shen, YJ, Shorten, M, Signorile, F, Singh, A, Sohoni, S, Somani, A, Sorensen, TK, Soria- Frisch, A, Staines Urias, E, Stein, A, Stones, W, Taori, V, Tayade, K, Todros, T, Uauy, R, Varalda, A, Venkataraman, M, Victora, C, Villar, J, Vinayak, S, Waller, S, Walusuna, L, Wang, JH, Wang, L, Wanyonyi, S, Weatherall, D, Wiladphaingern, S, Wilkinson, A, Wilson, D, Wu, MH, Wu, QQ, Wulff, K, Yellappan, D, Yuan, Y, Zaidi, S, Zainab, G, Zhang, JJ, Zhang, Y, Fung, Russell, Villar, Jose, Dashti, Ali, Ismail, Leila Cheikh, Staines-Urias, Eleonora, Ohuma, Eric O, Salomon, Laurent J, Victora, Cesar G, Barros, Fernando C, Lambert, Ann, Carvalho, Maria, Jaffer, Yasmin A, Noble, J Alison, Gravett, Michael G, Purwar, Manorama, Pang, Ruyan, Bertino, Enrico, Munim, Shama, Min, Aung Myat, McGready, Rose, Norris, Shane A, Bhutta, Zulfiqar A, Kennedy, Stephen H, Papageorghiou, Aris T, and Ourmazd, Abbas

Published
2020
Full Text
View/download PDF

14. Blood transfusion in children at a university hospital in a middle-income country: The need to reinforce adherence to current guidelines

Author

Villarreal-Martínez, L., Cázares-Perales, E., Domínguez-Varela, I., Godoy-Salinas, E., Villarreal-Martinez, D., Gutiérrez-Fernández, D., Meléndez-Aguirre, A., Guzmán-Gallardo, F., Treviño-Garza, C., Estrada-Rivera, E., de la O-Cavazos, M., Pérez-Chávez, F., Jaime-Pérez, J., and Gómez-Almaguer, D.

Published
2020
Full Text
View/download PDF

16. Globally, functional traits are weak predictors of juvenile tree growth, and we do not know why

Author

Paine, CET, Amissah, L, Auge, H, Baraloto, C, Baruffol, M, Bourland, N, Bruelheide, H, Daïnou, K, de Gouvenain, RC, Doucet, JL, Doust, S, Fine, PVA, Fortunel, C, Haase, J, Holl, KD, Jactel, H, Li, X, Kitajima, K, Koricheva, J, Martínez-Garza, C, Messier, C, Paquette, A, Philipson, C, Piotto, D, Poorter, L, Posada, JM, Potvin, C, Rainio, K, Russo, SE, Ruiz-Jaen, M, Scherer-Lorenzen, M, Webb, CO, Wright, SJ, Zahawi, RA, and Hector, A

Subjects
functional ecology, FunDivEurope, growth, hierarchical models, plant population and community dynamics, relative growth rate, size-standardized growth rate, TreeDivNet, Ecology, Environmental Sciences, Biological Sciences, Agricultural and Veterinary Sciences
Abstract

Plant functional traits, in particular specific leaf area (SLA), wood density and seed mass, are often good predictors of individual tree growth rates within communities. Individuals and species with high SLA, low wood density and small seeds tend to have faster growth rates. If community-level relationships between traits and growth have general predictive value, then similar relationships should also be observed in analyses that integrate across taxa, biogeographic regions and environments. Such global consistency would imply that traits could serve as valuable proxies for the complex suite of factors that determine growth rate, and, therefore, could underpin a new generation of robust dynamic vegetation models. Alternatively, growth rates may depend more strongly on the local environment or growth-trait relationships may vary along environmental gradients. We tested these alternative hypotheses using data on 27 352 juvenile trees, representing 278 species from 27 sites on all forested continents, and extensive functional trait data, 38% of which were obtained at the same sites at which growth was assessed. Data on potential evapotranspiration (PET), which summarizes the joint ecological effects of temperature and precipitation, were obtained from a global data base. We estimated size-standardized relative height growth rates (SGR) for all species, then related them to functional traits and PET using mixed-effect models for the fastest growing species and for all species together. Both the mean and 95th percentile SGR were more strongly associated with functional traits than with PET. PET was unrelated to SGR at the global scale. SGR increased with increasing SLA and decreased with increasing wood density and seed mass, but these traits explained only 3.1% of the variation in SGR. SGR-trait relationships were consistently weak across families and biogeographic zones, and over a range of tree statures. Thus, the most widely studied functional traits in plant ecology were poor predictors of tree growth over large scales. Synthesis. We conclude that these functional traits alone may be unsuitable for predicting growth of trees over broad scales. Determining the functional traits that predict vital rates under specific environmental conditions may generate more insight than a monolithic global relationship can offer. The most widely studied functional traits in plant ecology, specific leaf area, wood density and seed mass, were only weakly associated with tree growth rates over broad scales. Assessing trait-growth relationships under specific environmental conditions may generate more insight than a global relationship can offer.

Published
2015

30. Low 5-hydroxymethylcytosine level is an independent predictor of high histological grade in locally advanced breast cancer

Author

Navarro G, Villaseñor Y, Bargalló E, León Dcd, Ramírez M, Marco A. Andonegui, Reynoso N, Luis A. Herrera, Elena Colicino, Diddier Prada, Caro C, Peña-Curiel O, Garcia Am, Cortes Cc, Villarreal-Garza C, Castro-Belio T, Alejandro López-Saavedra, José Díaz-Chávez, Cabrera-Galeana P, and Cristian Arriaga-Canon

Subjects
5-Hydroxymethylcytosine, Oncology, medicine.medical_specialty, chemistry.chemical_compound, Breast cancer, chemistry, business.industry, Internal medicine, medicine, Locally advanced, business, Independent predictor, medicine.disease
Published
2020
Full Text
View/download PDF

35. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

41. 325P Trends of primary tumor resection in de novo metastatic breast cancer: The experience of a Mexican center

Author

Gonzalez-Mondellini, F.A., primary, Acosta-Sandoval, M.A., additional, Aranda-Gutierrez, A., additional, Ferrigno, A.S., additional, Roman-Zamudio, M., additional, Torres-Leal, M.I., additional, Becerril-Gaitan, A., additional, Vaca-Cartagena, B.F., additional, Ortiz-López, R., additional, Diaz-Perez, H.M., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

43. 1722P Prevalence and predictors of breast reconstruction following mastectomy in breast cancer patients treated in a public center in Mexico

Author

Becerril-Gaitan, A., primary, Vaca-Cartagena, B.F., additional, Ferrigno, A.S., additional, Aranda-Gutierrez, A., additional, Roman-Zamudio, M., additional, Acosta-Sandoval, M.A., additional, Torres-Leal, M.I., additional, Gonzalez-Mondellini, F.A., additional, Diaz-Perez, H.M., additional, Cardona-Huerta, S., additional, Ortiz-López, R., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

44. 190P Clinical features and recurrence-free survival among young patients with breast cancer

Author

Ferrigno, A.S., primary, Aranda-Gutierrez, A., additional, Becerril-Gaitan, A., additional, Vaca-Cartagena, B.F., additional, Gonzalez-Mondellini, F.A., additional, Acosta-Sandoval, M.A., additional, Roman-Zamudio, M., additional, Torres-Leal, M.I., additional, Treviño-Alanis, C.A., additional, Diaz-Perez, H.M., additional, Ortiz-López, R., additional, Cardona, S., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

45. 1850P Communication patterns and cascade testing among pathogenic variant carriers

Author

Aguilar, D., primary, Chavarri Guerra, Y., additional, Mesa-Chavez, F., additional, Vaca-Cartagena, B.F., additional, Becerril-Gaitan, A., additional, Aranda-Gutierrez, A., additional, Ochoa-Chavez, M.F., additional, Rodriguez-Faure, A., additional, Gonzalez-Santiesteban, S., additional, Franco-Jimenez, H.J.J., additional, Obregón-Leal, D., additional, Miaja-Avila, M., additional, Weitzel, J.N., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

46. 217P The impact of obesity on the survival outcomes of women with breast cancer that achieve pathological complete response

Author

Roman-Zamudio, M., primary, Gutierrez, A. Aranda, additional, Ferrigno, A.S., additional, Becerril-Gaitan, A., additional, Vaca-Cartagena, B.F., additional, Gonzalez-Mondellini, F.A., additional, Acosta-Sandoval, M.A., additional, Torres-Leal, M.I., additional, Diaz-Perez, H.M., additional, Cardona-Huerta, S., additional, Ortiz-López, R., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

47. 207P Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin

Author

Vaca-Cartagena, B.F., primary, Becerril-Gaitan, A., additional, Aranda-Gutierrez, A., additional, Ferrigno, A.S., additional, Roman-Zamudio, M., additional, Torres-Leal, M.I., additional, Acosta-Sandoval, M.A., additional, Gonzalez-Mondellini, F.A., additional, Diaz-Perez, H.M., additional, Cardona-Huerta, S., additional, Ortiz-López, R., additional, and Villarreal-Garza, C., additional

Published
2021
Full Text
View/download PDF

49. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Condorelli, M, Bruzzone, M, Ceppi, M, Ferrari, A, Grinshpun, A, Hamy, A S, de Azambuja, E, Carrasco, E, Peccatori, F A, Di Meglio, A, Paluch-Shimon, S, Poorvu, P D, Venturelli, M, Rousset-Jablonski, C, Senechal, C, Livraghi, L, Ponzone, R, De Marchis, L, Pogoda, K, Sonnenblick, A, Villarreal-Garza, C, Córdoba, O, Teixeira, L, Clatot, F, Punie, K, Graffeo, R, Dieci, M V, Pérez-Fidalgo, J A, Duhoux, Francois, Puglisi, F, Ferreira, A R, Blondeaux, E, Peretz-Yablonski, T, Caron, O, Saule, C, Ameye, L, Balmaña, J, Partridge, A H, Azim, H A, Demeestere, I, Lambertini, M, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Condorelli, M, Bruzzone, M, Ceppi, M, Ferrari, A, Grinshpun, A, Hamy, A S, de Azambuja, E, Carrasco, E, Peccatori, F A, Di Meglio, A, Paluch-Shimon, S, Poorvu, P D, Venturelli, M, Rousset-Jablonski, C, Senechal, C, Livraghi, L, Ponzone, R, De Marchis, L, Pogoda, K, Sonnenblick, A, Villarreal-Garza, C, Córdoba, O, Teixeira, L, Clatot, F, Punie, K, Graffeo, R, Dieci, M V, Pérez-Fidalgo, J A, Duhoux, Francois, Puglisi, F, Ferreira, A R, Blondeaux, E, Peretz-Yablonski, T, Caron, O, Saule, C, Ameye, L, Balmaña, J, Partridge, A H, Azim, H A, Demeestere, I, and Lambertini, M

Abstract

Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2 pathogenic variants. This is a multicenter retrospective cohort study across 30 centers worldwide including women diagnosed at ≤40 years with stage I-III breast cancer, between January 2000 and December 2012, harboring known germline BRCA1/2 pathogenic variants. Patients included in this analysis had a post-treatment pregnancy either achieved through use of ART (ART group) or naturally (non-ART group). ART procedures included ovulation induction, ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection, and embryo transfer under hormonal replacement therapy. Among the 1424 patients registered in the study, 168 were eligible for inclusion in the present analysis, of whom 22 were in the ART group and 146 in the non-ART group. Survivors in the ART group conceived at an older age compared with those in the non-ART group (median age: 39.7 versus 35.4 years, respectively). Women in the ART group experienced more delivery complications compared with those in the non-ART group (22.1% versus 4.1%, respectively). No other apparent differences in obstetrical outcomes were observed between cohorts. The median follow-up from pregnancy was 3.4 years (range: 0.8-8.6 years) in the ART group and 5.0 years (range: 0.8-17.6 years) in the non-ART group. Two patients (9.1%) in the ART group experienced a disease-free survival event (specifically, a locoregional recurrence) compared with 40 patients (27.4%) in the non-ART group. In the ART group, no patients deceased compared with 10 patients (6.9%) in the non-ART group. This study provides encouraging safety data on the use of ART in breast cancer survivors harboring germline pathogenic variants in BRCA1/2, when natural conception fails or when they opt for ART in order to carry out preimplantation genetic testi

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results